Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
1601 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Belgium 50
1602 Bone Marrow Allogeneic Myelodysplastic Syndrome Hematology 2024 Standard Therapy France 31
1603 Bone Marrow Allogeneic Chronic myelomonocytic leukemia Hematology 2024 Standard Therapy Italy 64
1604 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy France 10
1605 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 12
1606 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy USA 4
1607 Bone Marrow Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Canada 8
1608 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy Poland 17
1609 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy USA 8
1610 Bone Marrow Allogeneic Severe Aplastic Anemia Hematology 2024 Standard Therapy USA 67
1611 Bone Marrow Allogeneic Hodgkins Lymphoma Hematology 2024 Standard Therapy United Kingdom 36
1612 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 72
1613 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy USA 9
1614 Bone Marrow Allogeneic Chronic Granulomatous Disease Hematology 2024 Standard Therapy USA 3
1615 Apheresis Allogeneic A- Thalassemia Hematology 2024 Standard Therapy Poland 11
1616 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 13
1617 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 21
1618 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 22
1619 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 38
1620 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Germany 41
1621 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 44
1622 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 44
1623 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 48
1624 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 50
1625 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Germany 50
1626 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 55
1627 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 59
1628 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Germany 60
1629 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 63
1630 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 44
1631 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 59
1632 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 51
1633 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2024 Standard Therapy Poland 34
1634 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 1
1635 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 10
1636 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 20
1637 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 25
1638 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 26
1639 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 28
1640 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 34
1641 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 35
1642 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 37
1643 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 38
1644 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 38
1645 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 40
1646 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 41
1647 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 43
1648 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 51
1649 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 51
1650 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 51
1651 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 59
1652 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 59
1653 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 60
1654 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 60
1655 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 60
1656 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 61
1657 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 61
1658 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 62
1659 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 62
1660 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 64
1661 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 65
1662 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 66
1663 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 67
1664 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 67
1665 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 68
1666 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 69
1667 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 69
1668 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 69
1669 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 69
1670 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 69
1671 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 70
1672 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 70
1673 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 72
1674 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 73
1675 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 77
1676 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 59
1677 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 66
1678 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 58
1679 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 54
1680 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 29
1681 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 64
1682 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 27
1683 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 60
1684 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 63
1685 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 50
1686 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 60
1687 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 30
1688 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 68
1689 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 77
1690 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 60
1691 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 47
1692 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 62
1693 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 65
1694 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 64
1695 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 61
1696 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2024 Standard Therapy Poland 64
1697 Apheresis Allogeneic Acute Myelogenous Leukemia- Core-Binding Factor Hematology 2024 Standard Therapy Poland 68
1698 Apheresis Allogeneic Acute Myelogenous Leukemia, Post Myelofibrosis Hematology 2024 Standard Therapy Poland 63
1699 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 36
1700 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2024 Standard Therapy Germany 46
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?